The narrative presents private equity’s entry into women’s health as a market-driven solution to systemic underinvestment, framing it as a win-win for investors and patients. The strongest version of this argument acknowledges that capital infusion could spur innovation in diagnostics and treatments, addressing long-neglected gaps. However, the pattern of private equity prioritizing high-margin assets—like pathology—raises questions about whether profit motives will align with patient needs or e...